

FSTL3 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP12300b

Specification

FSTL3 Antibody (C-term) - Product Information

Application WB, IHC-P,E **Primary Accession** 095633 Other Accession NP 005851.1 Reactivity Human Host **Rabbit** Clonality **Polyclonal** Isotype Rabbit IgG **Antigen Region** 229-258

FSTL3 Antibody (C-term) - Additional Information

Gene ID 10272

Other Names

Follistatin-related protein 3, Follistatin-like protein 3, Follistatin-related gene protein, FSTL3, FLRG

Target/Specificity

This FSTL3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 229-258 amino acids from the C-terminal region of human FSTL3.

Dilution

WB~~1:1000 IHC-P~~1:25

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

FSTL3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

FSTL3 Antibody (C-term) - Protein Information

Name FSTL3

Synonyms FLRG





Function Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10.

Cellular Location [Isoform 1]: Secreted.

Tissue Location


Expressed in a wide range of tissues.

FSTL3 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

FSTL3 Antibody (C-term) - Images




Anti-FSTL3 Antibody (C-term) at 1:1000 dilution + A431 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 28 kDa Blocking/Dilution buffer: 5% NFDM/TBST.







Anti-FSTL3 Antibody (C-term) at 1:2000 dilution + HepG2 whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 28 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



FSTL3 Antibody (C-term) (Cat. #AP12300b) western blot analysis in CEM cell line lysates (35ug/lane). This demonstrates the FSTL3 antibody detected the FSTL3 protein (arrow).



AP12300B staining FSTL3 in human testis tissue sections by Immunohistochemistry (IHC-P -





Tel: 858.875.1900 Fax: 858.875.1999

paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.

FSTL3 Antibody (C-term) - Background

Follistatin-like 3 is a secreted glycoprotein of the follistatin-module-protein family. It may have a role in leukemogenesis.

FSTL3 Antibody (C-term) - References

Miron, P., et al. Prenat. Diagn. 30(3):224-228(2010) Thadhani, R., et al. Diabetes Care 33(3):664-669(2010) Bloise, E., et al. BMC Cancer 9, 320 (2009): Stamler, R., et al. J. Biol. Chem. 283(47):32831-32838(2008) Lara-Pezzi, E., et al. Endocrinology 149(11):5822-5827(2008)